Glenmark partners with Pfizer to launch abrocitinib in India to treat atopic dermatitis
Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO. Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO). It is also approved by the USFDA, European Medicines Agency (EMA), and other regulatory agencies.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Dermatitis | Dermatology | European Medicines Agency (EMA) | India Health | Marketing | Pfizer | Pharmaceuticals